NEWTON, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. ALNA, a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Alexey Margolin, Ph.D., Allena's Chief Executive Officer, will present a corporate update at two investor conferences in October:
Ladenburg Thalmann 2018 Healthcare Conference
Date: Tuesday, October 2, 2018
Time: 10:00 a.m. ET
Location: New York, NY
2018 Cantor Global Healthcare Conference
Date: Wednesday, October 3, 2018
Time: 4:00 p.m. ET
Location: New York, NY
Live audio webcasts of both presentations will be available under "Events and Presentations" in the Investors section of the Company's website at www.allenapharma.com. Replays of the webcasts will be available on the Allena website for 30 days following each presentation.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena's lead product candidate, ALLN-177, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.
Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannahd@sternir.com
Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
